EPISODE 23 | 14 MIN | 27 Sep. 2022
InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China
EPISODE 23 | 14 MIN | 27 Sep. 2022
#Drug Review #R&D #Business #Listing
InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China
Play
Summary
This week, in China, Nanjing Biosnwill Pharma's Class 2.2 new drug Edaravone Sublingual Tablets and Yichang Humanwell's Class 3 generic drug Clobazam Tablets have been approved by the NMPA for marketing. Meanwhile, new indications have been approved for both Junshi Biosciences' Toripalimab and AstraZeneca's Olaparib Tablets; New progress with the EMA and FDA approvals has been achieved for some popular drugs. For example, Roche's bispecific antibody ophthalmic drug Faricimab has been approved for marketing in the EU. Although there has been nothing new in R&D during the week, on the business side, Chiatai Tianqing entered into a collaboration agreement with Inventiva for the development of lanifibranor, a pan-PPAR agonist. Besides, InnoCare Pharma was successfully listed on the STAR.
Timeline
1
PART1 | 01:20
A new indication for Junshi Biosciences' Toripalimab in combination with standard first-line chemotherapy, was approved for marketing
2
PART2 | 01:46
The new indication for AstraZeneca/ MSD's PARP inhibitor Olaparib Tablets was approved for marketing
3
PART3 | 02:24
Nanjing Biosnwill Pharma's new class 2.2 drug Edaravone Sublingual Tablets was approved for marketing
4
PART4 | 02:51
Yichang Humanwell's Class 3 generic drug Clobazam Tablets was approved for marketing
5
PART5 | 03:20
The marketing application for Orphalan 5.1 class new drug Trientine Hydrochloride Film-coated Tablets was submitted and processed
6
PART6 | 03:46
The marketing application for Pediatrix Therapeutics and Tris Pharma's new class 5.1 drug Methylphenidate Hydrochloride Oral Sustained-release for Suspension was submitted and processed
7
PART7 | 04:23
Otsuka Pharmaceutical's Difamilast Ointment was approved for the clinical treatment of atopic dermatitis in children and adults
8
PART8 | 04:47
Ribo Bio's RBD7022 Injection was approved for clinical treatment of primary hypercholesterolemia or mixed hyperlipidemia featuring elevated LDL cholesterol
9
PART9 | 05:16
Innovent's IBI333 was approved for clinical treatment of neovascular and age-related macular degeneration
10
PART10 | 05:45
Ori-C101 Injection from Oricell Therapeutics was approved for clinical treatment of advanced hepatocellular carcinoma
11
PART11 | 06:13
The clinical trial application for BRL-201 submitted by BRL Medicine was accepted
12
PART12 | 06:43
Lepu Biopharma's MRG003 for injection is proposed to be included in the breakthrough therapy designation
13
PART13 | 07:20
A new indication of Eli Lilly's Selpercatinib for the treatment of patients with locally advanced or metastatic solid tumors with RET gene fusions was approved by the FDA
14
PART14 | 07:50
Cidara and Melinta Therapeutics jointly announced that the FDA has processed a marketing application for Rezafungin
15
PART15 | 08:19
Argenx announced that the FDA has processed a Biologics License Application for subcutaneous injection of Efgartigimod for the treatment of adult patients with generalized myasthenia gravis
16
PART16 | 08:49
Antengene Corporation's self-developed novel PD-L1/4-1BB bispecific antibody ATG-101 injection was granted orphan drug designation by the FDA
17
PART17 | 09:37
Roche announced that Faricimab was approved for marketing by the EMA for the treatment of nAMD and visual impairment due to DME
18
PART18 | 10:00
AstraZeneca's Tezepelumab was approved by the EMA for marketing as an additional maintenance treatment for patients aged 12 years and above with severe asthma
19
PART19 | 10:35
EMA accepted two marketing authorization applications of UCB'S Bimekizumab for the treatment of adults with PsA and axSpA
20
PART20 | 11:00
Merck to Initiate new phase 3 clinical program with lower dose of daily oral Islatravir in combination with doravirine for treatment of people with HIV-1 infection
21
PART21 | 11:31
Fosun Pharmaceutical started an international multicenter phase II clinical trial of SurVaxM in combination with temozolomide for adjuvant treatment of glioblastoma in primary diagnosis
22
PART22 | 12:01
Pfizer unveiled the latest study data for PF-06882961 and PF-07081532 which showed significant results for glucose-lowering and weight loss compared to placebo
23
PART23 | 12:28
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus in China
24
PART24 | 12:57
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
25
PART25 | 13:28
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
You can listen and/or download the episode on Podbean, or directly through iTunes, GooglePlay, Amazon Music and Samsung Podcasts. You can also subscribe our podcast by RSS feed, please copy the full URL below.
RSS Feed:
https://feed.podbean.com/PharmaSources/feed.xml
https://feed.podbean.com/PharmaSources/feed.xml
Copy Feed
Full Transcript